Ophthalmic manifestations of herpes zoster virus in patients with multiple myeloma following bone marrow transplantation

BMJ Case Reports

Volumn , Issue , 2013, Pages

  Khalafallah, Alhossain A ^a,b   Woodgate, Miriam ^a   Koshy, Kurien ^a   Patrick, Andrew ^c  

^a LAUNCESTON GENERAL HOSPITAL   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c The Eye Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BORTEZOMIB; CHLORAMPHENICOL; DEXAMETHASONE; FAMCICLOVIR; IMMUNOGLOBULIN KAPPA CHAIN; LENALIDOMIDE; MELPHALAN; PARAPROTEIN; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONJUNCTIVITIS; CORNEA DISEASE; CORNEA PSEUDODENDRITES; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EYE PAIN; EYE SWELLING; FEMALE; HEADACHE; HERPES ZOSTER OPHTHALMICUS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LUMBAR PUNCTURE; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OPTIC NEURITIS; PLASMACYTOSIS; PLEOCYTOSIS; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PROTEINURIA; RETROBULBAR OPTIC NEUROPATHY; TREATMENT RESPONSE; VISUAL IMPAIRMENT;

EID: 84875959736     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2012-007625     Document Type: Article

References (17)

1. Mahindra A, Laubach J, Raje N, et al. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 2012;9:135-43.
2. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98. (Pubitemid 41007864)
3. Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, firstin- class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003;10:361-9. (Pubitemid 37296062)
4. Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008;29:4784-9.
5. Kim SJ, Kim K, Kim BS, et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymphoma Leukaemia Myeloma 2008;8:237.40.
6. Chanan-Khan AA, Sonneveld P, Schuster MW, et al. Analysis of varicella zoster virus reactivation among bortezomib-treated patients in the APEX study. Blood 2006;108:1009.
7. Morison WL. Herpes simplex and herpes zoster in neoplasia. Lancet 1974;1:1293.
8. Khalafallah A, Maiwald M, Cox A, et al. Effect of immunoglobulin therapy on the rate of infections in multiple myeloma patients undergoing autologous stem cell transplantation or treated with immunomodulatory agents. Medit J Hemat Infect Dis 2009;2:1.
9. Schuchter LM, Wingard JR, Piantadosi S, et al. Herpes zoster infection after autologous bone marrow transplantation. Blood J 1989;74:1424-7. (Pubitemid 19227457)
10. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009;49:1121.
11. Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006;107:3575-83.
12. Thomas J, Liesegang MD. Herpes zoster ophthalmicus: natural history, risk factors, clinical presentation, and morbidity. Ophthalmology 2008;115:2-5.
13. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32. (Pubitemid 350146107)
14. Liesegang TJ. Varicella-zoster virus eye disease. Cornea 1999;18:511-31. (Pubitemid 29416245)
15. Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005;20:748-53. (Pubitemid 41141008)
16. Jurisic V, Colovic N, Konjevic G, et al. An aggressive extramedullary cutaneous plasmacytoma associated with extreme alterations in the innate immune system. Onkologie 2010;33:113-15.
17. Jurisic V, Srdic T, Konjevic G, et al. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol 2007;24:312-17. (Pubitemid 350135953)